Copyright © Inderes 2011 - present. All rights reserved.
Press release

Brain+ A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market

Brain+

Copenhagen, Denmark, 2 October 2024 - Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ A/S ("Brain+" or "the Company") recently obtained certification and regulatory registration of Ayla - your CST Assistant as a Medical Device Software in the United Kingdom (UK). Subsequently, the product has now been released for sale. Ayla - your CST Assistant is the only UK certified digital solution to offer scalable, high-quality delivery of Cognitive Stimulation Therapy (CST), which is the only non-pharmacological dementia therapy that is recommended in the UK national health guidelines. Release means that Ayla - your CST Assistant has been made available to dementia therapists and clinicians for download from all relevant distribution platforms, including App Store, Google Play and through the web. Brain+ can now start in earnest to execute on its UK sales plan, targeting the first UK sales contracts to be in place by end 2024 and annual recurring revenue (ARR) of DKK 7-8 million by end 2025 growing to ARR of DKK 25-27 million by end 2027.

Brain+, an innovator in healthtech solutions and building the world's first scalable dementia care platform, informs to now successfully have launched its first product, Ayla - your CST Assistant, as planned into the UK market. The launch follows the recent UK regulatory registration of Ayla - your CST Assistant as a certified Medical Device Software (UKCA mark).  

Devika Wood, Chief Commercial Officer, Brain+ commented on the UK launch of Ayla - your CST Assistant:

"Our team has been dedicated to achieving this major milestone, working diligently to release in line with our UK launch strategy.  I truly see Ayla - your CST Assistant as a groundbreaking solution, providing a platform that allows more people with dementia to benefit from Cognitive Stimulation Therapy (CST). Now commercially available as a certified Medical Device Software absolutely solidifies the product's relevance and leading market position. We have been met with very positive interest for our offering, and we can now accelerate the execution of our commercialization plan. I remain confident in our ability to build a strong pipeline of sales and partnership leads through this quarter and remain committed to signing our first UK contract with dementia care sites under the National Health Service (NHS) before the end of 2024 as the outset for commercial scaling in 2025."

Following its commercial release, Ayla - your CST Assistant is now available to dementia therapists and clinicians for download on iPads, tablets, and other devices through all relevant software distribution platforms, including the App Store, Google Play, and the web to cater for the diverse range of devices and platforms being used in the UK health care system. Specifically, the product can be accessed here:

With the UK launch of Ayla - your CST Assistant realized according to plan, Brain+ remains confident in its ability to build its market presence and secure the first sales contracts in 2024. The Company retains earlier communicated expectations of reaching annual recurring revenue (ARR) of DKK 7-8 million by end 2025 and ARR of DKK 25-27 million by end 2027.

Upcoming UK commercial milestones in 2024
  • Early October - Launch new Brain+ corporate branding and awareness campaign
Build a strong and recognizable brand to support the commercial introduction of the Ayla suite of products as unique and valuable CST offerings to support dementia care and management.
  • October - Start targeted commercial outreach
Reach out to identified relevant key CST stakeholders and NHS dementia decision makers to present Ayla - your CST Assistant and its clinical benefits
  • October - Publish White Paper on Ayla - your CST Assistant
The White Paper will highlight the documented clinical benefits of the product as a new and innovative approach to high-quality and scalable CST delivery that actively addresses the current barriers to scaled adoption of this highly relevant therapy in the UK. 
  • October - Host webinar with key partners and CST advocates
The webinar will introduce key dementia care stakeholders to the benefits and potential of CST and to Ayla - your CST Assistant as a valuable tool for scalable delivery of CST, thus bringing the white paper and its core messaging to life. 
  • October onwards - Build pipeline of active customer leads among NHS Trusts and other institutions offering CST
  • November/December - Close the first NHS `Evaluation Track` sales contracts

NHS `Evaluation Track' contracts typically range values of £10,000-30,000. Such early contracts are expected to set the basis for the transition into larger, recurring SaaS contracts with the NHS from 2025.

The important achievement of first product launch into a major dementia market marks the starting point for Brain+ on its path to expand its reach and offerings to deliver cutting-edge solutions to healthcare professionals globally to alter how dementia is being treated and managed.

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31 39 33 17 (SMS), kim@brain-plus.com

Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia in 2030.

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.